PRA’s remote patient monitoring platform to combine with HGH treatment system

KUALA LUMPUR, April 8 -- PRA Health Sciences announced that Merck KGaA, Darmstadt, Germany, known in the United States as EMD Serono, has selected PRA’s remote patient monitoring platform to work in combination with its human growth hormone (HGH) treatment system.

Under this agreement, PRA’s remote patient monitoring platform backs Merck KGaA, Darmstadt, Germany’s HGH treatment system, including growlink™, a mobile app for patients prescribed with HGH treatment, and easypod® Connect, a secure platform for healthcare professionals (HCP) in the field of endocrinology.

This is to monitor patients’ adherence, review injection history, and share information about patients’ progression with growth hormone disorder, according to a statement.

“Our collaboration with Merck KGaA, Darmstadt, Germany to support growlink and easypod Connect is an example of how the industry is advancing with the patient at the centre of our innovation,” said PRA Health Sciences Executive Vice President and Chief Scientific Officer, Kent Thoelke.

Adding this layer of technology to HGH treatments better facilitates patient engagement, helps HCPs make better use of patient visits, and ensures the treatment is taken regularly and at the right dosage, optimising treatment outcome and driving payer confidence.

In a real-world setting, an HCP would use easypod Connect to invite patients to download growlink. Then, the patient downloads the mobile app, signs an eConsent form on the app, and syncs the app with Merck KGaA, Darmstadt, Germany’s HGH injector medical device, easypod.

This device is able to self-regulate the appropriate dosage of HGH based on the treatment protocol.

The four-part system – Merck KGaA, Darmstadt, Germany’s mobile app (growlink), connected device (easypod), and HCP platform (easypod Connect) underpinned by PRA’s remote patient monitoring technology – enables HCPs to see an accurate picture of patients’ adherence, height, weight, and other outcomes while offering patients a more convenient way to follow to their treatment regimen and manage their condition.

More details at www.prahs.com.

-- BERNAMA